PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2176369
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2176369
Introduction
Testing for genetically modified organisms has become a routine checkpoint in global food and feed trade. Laboratories screen seed, grain, processed foods and animal feed to confirm whether approved or unapproved genetic events are present, and to verify the labelling claims that buyers and regulators rely on. In 2026, the market is valued at US$2.2 Bn and is projected to reach US$3.6 Bn by 2033, registering a CAGR of 7.30%. Demand rests on a simple reality: trading partners do not approve new genetic events at the same time, so consignments crossing borders must be checked again and again. On top of legal requirements, private non-GMO and organic verification programmes generate additional sample volumes that no statute mandates. Laboratories are responding by broadening their method portfolios, from established polymerase chain reaction assays to sequencing tools capable of identifying unknown constructs. Meanwhile, per-sample price pressure and the technical difficulty of analysing heavily processed products continue to shape how service providers compete, invest and position their offerings.
Market Insights
The market is organised across four dimensions: offering, technology, sample type and end user. Offerings include testing services, kits and reagents, and certified reference materials with proficiency testing schemes. Technology choices span real-time and digital polymerase chain reaction, end-point polymerase chain reaction with multiplex screening, immunoassay and lateral flow strip tests, and next-generation sequencing. Samples analysed cover seed, grain and raw commodities, processed food and animal feed, while end users range from contract and commercial testing laboratories to in-house manufacturer laboratories, seed company laboratories and government and border control laboratories. Next-generation sequencing is the fastest-growing technology, advancing at a 12.4% CAGR as laboratories seek methods that can detect events not covered by targeted assays. Kits and reagents are expanding at 8.1%, reflecting stronger in-house testing activity, and processed food is the fastest-growing sample type at 8.4%. Policy remains a major trend, with the European Commission proposing new genomic techniques legislation in July 2023 and the European Parliament adopting its first-reading position in February 2024.
Drivers
The most powerful growth force is asynchronous approval of genetic events across trading partners, a high-impact driver over the short term. When one country authorises a new event before its importers do, exporters and buyers must screen grain consignments repeatedly to avoid rejected shipments and costly recalls. Every gap between approval calendars translates directly into additional test volumes for laboratories at origin and destination. The second driver is the expansion of private non-GMO and organic verification schemes, which carry medium impact over the medium term. These programmes require testing that no law demands, yet retailers and brand owners rely on them to protect label claims and consumer trust. Together, regulatory mismatch and voluntary assurance keep sample flows steady. These drivers operate against clear restraints. Per-sample price competition compresses laboratory margins in the short term, and degraded DNA in processed foods, along with rising method maintenance costs, limits analytical reliability over the long term, pushing providers toward more robust and efficient testing approaches.
Business Opportunity
Two openings stand out for laboratories and technology suppliers. The first lies in the unresolved rules governing new genomic techniques. While legislation remains under discussion, food and feed businesses face uncertainty about how gene-edited products will be classified, labelled and traced. That uncertainty creates demand for documentation services, regulatory support and advanced analysis capable of characterising edits that conventional methods may not detect. Providers that combine laboratory capability with traceability expertise are well placed to capture this work as clarity gradually emerges. The second opportunity comes from next-generation sequencing, which opens an identification market that targeted assays cannot serve. Traditional polymerase chain reaction methods look for known sequences, but sequencing can reveal unexpected or unauthorised constructs in a single run. This capability appeals to regulators, border authorities and major traders that need assurance beyond a fixed screening panel. As sequencing costs fall and bioinformatics tools mature, laboratories offering these services can differentiate on depth of insight rather than competing purely on price per sample.
Region Analysis
Europe leads the market with 36.4% of 2026 revenue, supported by strict labelling expectations, extensive border checks and active debate over new genomic techniques. Its laboratories handle large volumes of imported grain and feed, and the policy discussion around gene-edited products adds further analytical work. North America holds 27.8% of revenue, reflecting its role as a major producer and exporter of biotech crops whose shipments must satisfy the requirements of many destination markets. Asia Pacific accounts for 24.1% and is the fastest-growing region, advancing at a 9.1% CAGR as import controls tighten, domestic testing capacity grows and food manufacturers invest in their own laboratories. Latin America represents 7.4% of revenue, with testing linked closely to export-oriented grain and oilseed supply chains that must clear differing approval regimes abroad. The Middle East and Africa holds 4.3%, a smaller base where demand is tied to imported food and feed and to the gradual development of government and border control laboratory networks.
Key Players
Segmentation